Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 12, 2025
REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.
